Overview To Evaluate Safety, Tolerability and Pharmacodynamics of DWRX2003 Against COVID-19 (in Philippines) Status: Terminated Trial end date: 2021-03-23 Target enrollment: Participant gender: Summary This study is designed to assess the safety and tolerability of single doses of DWRX2003 in COVID-19 patients. Phase: Phase 1 Details Lead Sponsor: Daewoong Pharmaceutical Co. LTD.